242 related articles for article (PubMed ID: 23488865)
1. Latest advances in the discovery of fatty acid amide hydrolase inhibitors.
Bisogno T; Maccarrone M
Expert Opin Drug Discov; 2013 May; 8(5):509-22. PubMed ID: 23488865
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).
Lodola A; Castelli R; Mor M; Rivara S
Expert Opin Ther Pat; 2015; 25(11):1247-66. PubMed ID: 26413912
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the discovery and evaluation of fatty acid amide hydrolase inhibitors.
Deng H
Expert Opin Drug Discov; 2010 Oct; 5(10):961-93. PubMed ID: 22823990
[TBL] [Abstract][Full Text] [Related]
4. Advances in the discovery of fatty acid amide hydrolase inhibitors: what does the future hold?
Fazio D; Criscuolo E; Piccoli A; Barboni B; Fezza F; Maccarrone M
Expert Opin Drug Discov; 2020 Jul; 15(7):765-778. PubMed ID: 32292082
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Schweitzer BA; Wilcox MV; McDonald J; Smith SE; Foltin S; Rumsey J; Yang YS; Walker MC; Kamtekar S; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6545-53. PubMed ID: 21924613
[TBL] [Abstract][Full Text] [Related]
6. Fatty acid amide hydrolase inhibitors display broad selectivity and inhibit multiple carboxylesterases as off-targets.
Zhang D; Saraf A; Kolasa T; Bhatia P; Zheng GZ; Patel M; Lannoye GS; Richardson P; Stewart A; Rogers JC; Brioni JD; Surowy CS
Neuropharmacology; 2007 Mar; 52(4):1095-105. PubMed ID: 17217969
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid amide hydrolase: from characterization to therapeutics.
Labar G; Michaux C
Chem Biodivers; 2007 Aug; 4(8):1882-902. PubMed ID: 17712824
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Walker MC; Schweitzer BA; Madsen HM; Tenbrink RE; McDonald J; Smith SE; Foltin S; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6538-44. PubMed ID: 21924614
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
10. The fatty acid amide hydrolase (FAAH).
Deutsch DG; Ueda N; Yamamoto S
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):201-10. PubMed ID: 12052036
[TBL] [Abstract][Full Text] [Related]
11. The Potential of Inhibitors of Endocannabinoid Metabolism for Drug Development: A Critical Review.
Fowler CJ
Handb Exp Pharmacol; 2015; 231():95-128. PubMed ID: 26408159
[TBL] [Abstract][Full Text] [Related]
12. (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Holtfrerich A; Hanekamp W; Lehr M
Eur J Med Chem; 2013 May; 63():64-75. PubMed ID: 23455058
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system.
Fezza F; De Simone C; Amadio D; Maccarrone M
Subcell Biochem; 2008; 49():101-32. PubMed ID: 18751909
[TBL] [Abstract][Full Text] [Related]
14. Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase.
Scott CW; Tian G; Yu XH; Paschetto KA; Wilkins DE; Meury L; Cao CQ; Varnes J; Edwards PD
Eur J Pharmacol; 2011 Sep; 667(1-3):74-9. PubMed ID: 21645511
[TBL] [Abstract][Full Text] [Related]
15. A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.
Gattinoni S; Simone CD; Dallavalle S; Fezza F; Nannei R; Battista N; Minetti P; Quattrociocchi G; Caprioli A; Borsini F; Cabri W; Penco S; Merlini L; Maccarrone M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4406-11. PubMed ID: 20591666
[TBL] [Abstract][Full Text] [Related]
16. High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
Wang Y; Ramirez F; Krishnamurthy G; Gilbert A; Kadakia N; Xu J; Kalgaonkar G; Ramarao MK; Edris W; Rogers KE; Jones PG
J Biomol Screen; 2006 Aug; 11(5):519-27. PubMed ID: 16760367
[TBL] [Abstract][Full Text] [Related]
17. A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents.
Tripathi RKP
Eur J Med Chem; 2020 Feb; 188():111953. PubMed ID: 31945644
[TBL] [Abstract][Full Text] [Related]
18. FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Petrosino S; Di Marzo V
Curr Opin Investig Drugs; 2010 Jan; 11(1):51-62. PubMed ID: 20047159
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications.
Quistad GB; Sparks SE; Segall Y; Nomura DK; Casida JE
Toxicol Appl Pharmacol; 2002 Feb; 179(1):57-63. PubMed ID: 11884237
[TBL] [Abstract][Full Text] [Related]
20. Structure based design of novel irreversible FAAH inhibitors.
Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
